習近平倡進一步發展中醫藥 走中西醫結合道路
《新華社》報道,國家主席習近平昨日(12日)在河南省南陽市視察,並先後來到醫聖祠和南陽藥益寶艾草製品有限公司,了解中醫藥發展和艾草製品產業發展情況。習近平指出,經過抗擊新冠肺炎疫情、非典等重大傳染病之後,對中醫藥的作用有了更深的認識,提倡要發展中醫藥,注重用現代科學解讀中醫藥學原理,走中西醫結合的道路。
消息刺激一眾中醫藥股造高,A股華神科技(000790.SZ)漲停。西藏藥業(600211.SH)、葫蘆娃(605199.SH)、同仁堂(600085.SH)現升3.7%至9.3%。
港股現代中藥集團(01643.HK)、中國中藥(00570.HK)現分別升5.7%及1.8%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.